Exact Sciences Corporation (EXAS) rated Buy with price target $13 by Auriga
Auriga rated Buy Exact Sciences Corporation (NASDAQ: EXAS) on 02/24/2012, when the stock price was $9.33. Since
then, Exact Sciences Corporation has gained 13.40% as of 05/22/2013's recent price of $10.58. If you would have followed this Auriga's recommendation on EXAS, you would have gained 13.39% of your investment in 453 days.
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.
operates full-service institutional equity and fixed income trading desks with state-of-the-art communications technology and trading systems. Through our U.S. corprate parent, Auriga
Holdings, LLC we offer a variety of services including whole loan trading and asset management. Through our Spanish parent company, Auriga
Securities Sociedad de Valores, S.A., we offer the ability to trade European equity and fixed income products. We connect electronically to buy-side firms; route orders to multiple points of execution and subsequently route to our clearing firm, Pershing, for settlement.